Cadenza Bio

Cadenza Bio is a private, preclinical biotech leveraging a novel approach to targeting Estrogen Receptor β (ERβ) with oral small molecules. The company aims to move beyond symptom management in diseases like multiple sclerosis and endometriosis, seeking to halt progression and promote repair. Founded by experienced scientists and led by a lean team with strong advisory boards, Cadenza is positioned to address significant unmet needs in neuroinflammation and women's health. As a preclinical entity, its success hinges on advancing its lead candidates into clinical trials and securing substantial partnership or investment capital.

Discovery and development of novel, oral small-molecule drugs selectively targeting Estrogen Receptor β (ERβ) to harness its anti-inflammatory, neuroprotective, and remyelinating properties.

In MS, Cadenza faces competition from other remyelination/repair-focused biotechs (e.g., targeting LINGO-1, muscarinic receptors) and large pharma with deep immunology pipelines. In endometriosis, competitors range from new hormonal therapies to non-hormonal approaches targeting inflammation or angiogenesis. Cadenza's differentiation lies in its oral, selective ERβ agonist approach aiming for both anti-inflammatory and repair mechanisms.